DDX17 and heart failure: Our results also revealed the mechanism of the DDX17-BCL6-DRP1 signaling pathway in heart failure, which could be used as a potential therapeutic target for the mitochondrial dysregulation-induced cardiovascular diseases, including myocardial ischemia-reperfusion injury, myocardial infarction, and heart failure.